Cultured Cells, Tissues, & Clinical Trials

IND (Investigational New Drug Application) is submitted after preclinical trials.
NDA (New Drug Application) is submitted after clinical trials, after FDA approval.

Designed to answer specific questions related to a condition.
Requires a protocol to ensure procedures are repeatable and reproducible across different locations.
- This ensures results can be validated, following the scientific method.
- Example: If tumor shrinkage differs significantly between trials in different regions due to procedural variations, comparison and validation become impossible.
Phases assess safety and efficacy in humans, dosage, and adverse reactions/side effects.
Clinical trials test different dosages to ascertain adverse reactions; adverse reactions such as heart problems, stomach problems, rashes, bleeding, and headaches must be documented.
- Pharmaceutical commercials list side effects, stemming from clinical trial documentation. This stems from the reality that not everyone reacts the same way.

Participants are grouped based on similarities and diversity to broaden the range of potential reactions.
Each phase requires a larger group of participants.
Continuous communication with the FDA is essential; trials may be terminated due to adverse reactions, which must be reported to the FDA.
After a sufficient number of trials (e.g., four or five), a marketing authorization (MAA/MNA) may be filed, allowing marketing and sale of the drug.
- Real-world data is collected post-marketing through surveys and special phones to monitor patient experiences, symptoms, and adherence.
- CROs (Clinical Research Organizations) often manage clinical trials and data collection.
Emergency Use Authorization: During COVID, preclinical and Phase 1 trials were followed by real-world data collection due to the emergency situation.
Adequate data from at least two large, controlled clinical trials is typically required for NDA/BLA submission and FDA approval.
Exceptions to Phase Testing:
- Emergency authorization: Applies in cases of nuclear terrorism or biological/chemical threats impacting a large population; Phase 2 and 3 trials may be bypassed initially.
- Orphan drugs: Benefit small patient populations with rare conditions. Due to a small population set, face testing is circumvented and beneficiaries are monitored to see what happens.

Allocation: The method used to assign participants to a specific arm.
Arm: A group of participants, categorized by factors like gender, race, ethnicity, age, or condition.
Randomized study: Participants are randomly assigned to groups (e.g., using a lottery system).
- Aim is to mitigate bias.
Nonrandomized study: Participants are categorized for specific reasons, introducing biases based on factors the research team is intending to observe.
- These categories may be things like age (6-12, 13-18) or race. These specific groupings introduce bias.
Placebo: An inactive substance given as a control in trials.

Crossover assignment: Two groups (Arm A and Arm B) receive opposite treatments at different times.
- Arm A gets Drug A, then Drug B; Arm B gets Drug B, then Drug A.
Open trial: All participants and researchers know who is receiving what treatment.
- High potential for bias.
Single-blind trial: Participants are unaware of the treatment they are receiving.
Double-blind trial: Neither participants nor staff know treatment assignments; preferred to reduce bias.
Triple-blind trial: The analyst analyzing the data also doesn't know who is getting what treatment. Very difficult to execute.

Patients categorized by severity of illness, time of onset, and risk factors are given a drug or a sugar pill.
Neither patients nor staff know who receives what.
This is a nonrandomized, double-blind, placebo study.

Patients with newly diagnosed glioblastoma are treated with three experimental therapies: isotretinoin, coxib (inhibitor), and thalidomide (anti-angiogenic).
Different drug combinations are tested (A, B, C; A+B, A+C, B+C, etc.).
The study is nonrandomized; Open trial is most probable.

NDA submission occurs after clinical trials.
INDA submission occurs before any clinical trials.
BLA (Biologics License Agreement) is for biologics and relates to patents.
Patents grant drug companies exclusive rights to sell a medication, allowing them to set prices.
After patent expiration, an ANDA (Abbreviated New Drug Application) allows generic production; generics must pass safety and efficacy testing but do not require clinical trials.

The FDA reviews applications, involving multiple experts and hearings, to ensure data validity.
The NDA/BLA tells the drug's full story, though new drugs may have incomplete data.

Biosimilars, like variations of Humira, undergo clinical trials to ensure they work similarly but may target different pathways or involve dosage/manufacturing changes. They can often use the prior clinical studies to prove efficiency.
A regular drug that is chemically synthesized undergoes an NDA rather than a BLA; the BLA is just for biologically derived products made from living organisms.
- Supplemental changes in formulation, labeling, or dosing require new submissions.

Routine inspections cover laboratories, manufacturing, clinical trials, and stability studies, with thorough record checks.
ANDAs are for generics, permissible only after the brand-name patent expires (typically 10-20 years).
Generics must demonstrate safety and efficacy but not clinical trials; bioequivalence studies compare them to brand-name drugs.
Bioequivalence Study: Used to determine that a generic drug functions the same as the branded version.

Inventors/researchers gain exclusive rights to their product, incentivising sales.
Utility patents: Patents on process, such as manufacturing.
Design patents: Patents on the look of the drug.
Plant patents: Patents that protect asexually reproduced plant varietals.

Aims to expedite drug approval by incorporating real-world evidence from Phase 4/5 trials post-marketing.
International regulations are also key, requiring companies to comply with diverse requirements from the European Union, Asia, and Japan.

Vedulista may be the drug name to research. The registry will say what the purpose of the study was (such as reproductive data). Limited Phase 1 trial is one such example.

In the clinical trial summary, it's more important to consider factors such as blind type, rather than highly specialized outcomes.
- CMax/AUC is very statistical, and requires a high level course in clinical trials.
If a trials says \"comparative study\" it's probably researching if a bioequivalent works the same.
A parallel assignment has group A and B getting the medicine you're observing. It has nothing to do with placebo.